Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia

Journal of Lipid Research

Volumn 44, Issue 11, 2003, Pages 2100-2108

  Verseyden, C ^a   Meijssen, S ^a   Van Dijk, H ^a   Jansen, H ^b   Castro Cabezas, M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acylation stimulating protein; Chylomicron; Free fatty acid; Insulin resistance; Postprandial lipemia

Indexed keywords

ATORVASTATIN; COMPLEMENT COMPONENT C3; FATTY ACID; HYDROXYBUTYRIC ACID; INSULIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIET RESTRICTION; DRUG MECHANISM; FAMILIAL HYPERLIPEMIA; FAT INTAKE; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN SENSITIVITY; LIPOLYSIS; LIPOPROTEIN SECRETION; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; CHYLOMICRONS; COMPLEMENT C3; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; MALE; POSTPRANDIAL PERIOD; PYRROLES; TRIGLYCERIDES;

EID: 0344236143     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M300201-JLR200     Document Type: Article

References (50)

1. Austin, M. A., B. McKnight, K. L. Edwards, C. M. Bradley, M. J. McNeely, B. M. Psaty, J. D. Brunzell, and A. G. Motulsky. 2000. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation. 101: 2777-2782.
2. Castro Cabezas, M., T. W. de Bruin, and D. W. Erkelens. 1992. Familial combined hyperlipidaemia: 1973-1991. Neth. J. Med. 40: 83-95.
3. Goldstein, J. L., H. G. Schrott, W. R. Hazzard, E. L. Bierman, and A. G. Motulsky. 1973. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 52: 1544-1568.
4. Keulen, E. T., M. Kruijshoop, N. C. Schaper, A. P. Hoeks, and T. W. de Bruin. 2002. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arterioscler. Thromb. Vasc. Biol. 22: 283-288.
5. Nikkila, E. A., and A. Aro. 1973. Family study of serum lipids and lipoproteins in coronary heart disease. Lancet. 1: 954-959.
6. Pitkanen, O. P., P. Nuutila, O. T. Raitakari, K. Porkka, H. Iida, I. Nuotio, T. Ronnemaa, J. Viikari, M. R. Taskinen, C. Ehnholm, and J. Knuuti. 1999. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation. 99: 1678-1684.
7. Rose, H. G., P. Kranz, M. Weinstock, J. Juliano, and J. I. Haft. 1973. Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype. Am. J. Med. 54: 148-160.
8. Voors-Pette, C., and T. W. de Bruin. 2001. Excess coronary heart disease in Familial Combined Hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis. 157: 481-489.
9. Ribalta, J., A. E. La Ville, J. C. Vallve, S. Humphries, P. R. Turner, and L. Masana. 1997. A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia. J. Lipid Res. 38: 1061-1069.
10. Veerkamp, M. J., J. de Graaf, S. J. Bredie, J. C. Hendriks, P. N. Demacker, and A. F. Stalenhoef. 2002. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler. Thromb. Vasc. Biol. 22: 274-282.
11. McNeely, M. J., K. L. Edwards, S. M. Marcovina, J. D. Brunzell, A. G. Motulsky, and M. A. Austin. 2001. Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study. Atherosclerosis. 159: 471-481.
12. Purnell, J. Q., S. E. Kahn, R. S. Schwartz, and J. D. Brunzell. 2001. Relationship of insulin sensitivity and ApoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 21: 567-572.
13. Ylitalo, K., K. V. Porkka, S. Meri, I. Nuotio, L. Suurinkeroinen, J. Vakkilainen, P. Pajukanta, J. S. Viikari, L. Peltonen, C. Ehnholm, and M. R. Taskinen. 1997. Serum complement and familial combined hyperlipidemia. Atherosclerosis. 129: 271-277.
14. Ylitalo, K., P. Pajukanta, S. Meri, R. M. Cantor, N. Mero-Matikainen, J. Vakkilainen, I. Nuotio, and M. R. Taskinen. 2001. Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 21: 838-843.
15. Allayee, H., K. L. Krass, P. Pajukanta, R. M. Cantor, C. J. van der Kallen, R. Mar, J. I. Rotter, T. W. de Bruin, L. Peltonen, and A. J. Lusis. 2002. Locus for elevated apolipoprotein B levels on chromosome 1p31 in families with familial combined hyperlipidemia. Circ. Res. 90: 926-931.
16. Aouizerat, B. E., H. Allayee, R. M. Cantor, R. C. Davis, C. D. Lanning, P. Z. Wen, G. M. Dallinga-Thie, T. W. de Bruin, J. I. Rotter, and A. J. Lusis. 1999. A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am. J. Hum. Genet. 65: 397-412.
17. Coon, H., R. H. Myers, I. B. Borecki, D. K. Arnett, S. C. Hunt, M. A. Province, L. Djousse, and M. F. Leppert. 2000. Replication of linkage of familial combined hyperlipidemia to chromosome 1q with additional heterogeneous effect of apolipoprotein A-I/C-III/A-IV locus. The NHLBI Family Heart Study. Arterioscler. Thromb. Vasc. Biol. 20: 2275-2280.
18. Dallinga-Thie, G. M., T. M. Linde-Sibenius, J. I. Rotter, R. M. Cantor, X. Bu, A. J. Lusis, and T. W. de Bruin. 1997. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. J. Clin. Invest. 99: 953-961.
19. Deeb, S. S., D. N. Nevin, L. Iwasaki, and J. D. Brunzell. 1996. Two novel apolipoprotein A-IV variants in individuals with familial combined hyperlipidemia and diminished levels of lipoprotein lipase activity. Hum. Mutat. 8: 319-325.
20. Pajukanta, P., I. Nuotio, J. D. Terwilliger, K. V. Porkka, K. Ylitalo, J. Pihlajamaki, A. J. Suomalainen, A. C. Syvanen, T. Lehtimaki, J. S. Viikari, M. Laakso, M. R. Taskinen, C. Ehnholm, and L. Peltonen. 1998. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat. Genet. 18: 369-373.
21. Pihlajamaki, J., J. Rissanen, S. Heikkinen, L. Karjalainen, and M. Laakso. 1997. Codon 54 polymorphism of the human intestinal fatty acid binding protein 2 gene is associated with dyslipidemias but not with insulin resistance in patients with familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 17: 1039-1044.
22. Ribalta, J., L. Figuera, J. Fernandez-Ballart, E. Vilella, M. Castro Cabezas, L. Masana, and J. Joven. 2002. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin. Chem. 48: 1597-1600.
23. Yang, W. S., D. N. Nevin, L. Iwasaki, R. Peng, B. G. Brown, J. D. Brunzell, and S. S. Deeb. 1996. Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. J. Lipid Res. 37: 2627-2637.
24. Castro Cabezas, M., T. W. de Bruin, H. W. de Valk, C. C. Shoulders, H. Jansen, and D. W. Erkelens. 1993. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J. Clin. Invest. 92: 160-168.
25. Karjalainen, L., J. Pihlajamaki, P. Karhapaa, and M. Laakso. 1998. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia? Arterioscler. Thromb. Vasc. Biol. 18: 1548-1553.
26. Meijssen, S., M. Castro Cabezas, T. B. Twickler, H. Jansen, and D. W. Erkelens. 2000. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J. Lipid Res. 41: 1096-1102.
27. Meijssen, S., H. van Dijk, C. Verseyden, D. W. Erkelens, and M. Castro Cabezas. 2002. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 22: 811-816.
28. Pihlajamaki, J., L. Karjalainen, P. Karhapaa, I. Vauhkonen, and M. Laakso. 2000. Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia, but insulin resistance is observed only in hypertriglyceridemic patients. Arterioscler. Thromb. Vasc. Biol. 20: 164-170.
29. Baldo, A., A. D. Sniderman, S. St. Luce, R. K. Avramoglu, M. Maslowska, B. Hoang, J. C. Monge, A. Bell, S. Mulay, and K. Cianflone. 1993. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J. Clin. Invest. 92: 1543-1547.
30. Saleh, J., L. K. Summers, K. Cianflone, B. A. Fielding, A. D. Sniderman, and K. N. Frayn. 1998. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J. Lipid Res. 39: 884-891.
31. Halkes, C.J., H. van Dijk, P. P. de Jaegere, H. W. Plokker, Y. van der Helm, D. W. Erkelens, and M. Castro Cabezas. 2001. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler. Thromb. Vasc. Biol. 21: 1526-1530.
32. Muscari, A., G. Massarelli, L. Bastagli, G. Poggiopollini, V. Tomassetti, U. Volta, G. M. Puddu, and P. Puddu. 1998. Relationship between serum C3 levels and traditional risk factors for myocardial infarction. Acta Cardiol. 53: 345-354.
33. Laine, P., M. O. Pentikainen, R. Wurzner, A. Penttila, T. Paavonen, S. Meri, and P. T. Kovanen. 2002. Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am. J. Cardiol. 90: 404-408.
34. Karpe, F., and A. Hamsten. 1994. Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J. Lipid Res. 35: 1311-1317.
35. Verseyden, C., S. Meijssen, and M. Castro Cabezas. 2002. Postprandial changes of apoB-100 and apoB-48 in TG rich lipoproteins in familial combined hyperlipidemia. J. Lipid Res. 43: 274-280.
36. Mohammadi, A., J. Macri, R. Newton, T. Romain, D. Dulay, and K. Adeli. 1998. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler. Thromb. Vasc. Biol. 18: 783-793.
37. Forster, L. F., G. Stewart, D. Bedford, J. P. Stewart, E. Rogers, J. Shepherd, C. J. Packard, and M. J. Caslake. 2002. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis. 164: 129-145.
38. Burnett, J. R., P. H. Barrett, P. Vicini, D. B. Miller, D. E. Telford, S. J. Kleinstiver, and M. W. Huff. 1998. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Arterioscler. Thromb. Vasc. Biol. 18: 1906-1914.
39. Boquist, S., F. Karpe, K. Danell-Toverud, and A. Hamsten. 2002. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia. Atherosclerosis. 162: 163-170.
40. Parhofer, K. G., P. H. Barrett, and P. Schwandt. 2000. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects. J. Clin. Endocrinol. Metab. 85: 4224-4230.
41. Sniderman, A. D., K. Cianflone, P. Arner, L. K. Summers, and K. N. Frayn. 1998. The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 18: 147-151.
42. Maslowska, M., T. Scantlebury, R. Germinario, and K. Cianflone. 1997. Acute in vitro production of acylation stimulating protein in differentiated human adipocytes. J. Lipid Res. 38: 1-11.
43. Karpe, F., M. Bell, J. Bjorkegren, and A. Hamsten. 1995. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler. Thromb. Vasc. Biol. 15: 199-207.
44. Mero, N., M. Syvanne, B. Eliasson, U. Smith, and M. R. Taskinen. 1997. Postprandial elevation of apoB-48-containing triglyceride-rich particles and retinyl esters in normolipemic males who smoke. Arterioscler. Thromb. Vasc. Biol. 17: 2096-2102.
45. Beylot, M. 1996. Regulation of in vivo ketogenesis: role of free fatty acids and control by epinephrine, thyroid hormones, insulin and glucagon. Diabetes Metab. 22: 299-304.
46. Brunzell, J. D., W. R. Hazzard, D. Porte, Jr., and E. L. Bierman. 1973. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J. Clin. Invest. 52: 1578-1585.
47. Karpe, F., and M. Hultin. 1995. Endogenous triglyceride-rich lipoproteins accumulate in rat plasma when competing with a chylomicron-like triglyceride emulsion for a common lipolytic pathway. J. Lipid Res. 36: 1557-1566.
48. Castro Cabezas, M., D. W. Erkelens, L. A. Kock, and T. W. de Bruin. 1994. Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides. Eur. J. Clin. Invest. 24: 669-678.
49. Castro Cabezas, M., T. W. de Bruin, L. A. Kock, W. Kortlandt, T. M. Linde-Sibenius, H. Jansen, and D. W. Erkelens. 1993. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism. 42: 497-503.
50. Parhofer, K. G., E. Laubach, and P. H. R. Barrett. 2003. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. J. Lipid Res. 44: 1192-1198.